via inrae.fr
An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
The intranasal vaccine contributed to multifaceted immune responses, leading to robust cross protection against influenza in mice. The vaccine consists of PEI-HA/CpG nanoparticles. PEI (polyethyleneimine), a robust and versatile delivery system, can simultaneously carry antigens (hemagglutinin, HA) that induce an immune response in the body, and adjuvants (CpG) that enhance the body’s immune response to an antigen for optimal immunoenhancement.
These comprehensive immune responses and cross protection were long lasting, exhibiting defense from influenza virus over six months after immunization. The findings are published in the journal ACS Applied Materials & Interfaces.
Intranasal vaccination is an ideal approach for infectious respiratory diseases such as influenza. Seasonal influenza vaccines generally induce narrow immune responses that rapidly decline, which leaves populations vulnerable to novel influenza strains. Advancements in influenza vaccine technology are needed to protect against a wide range of influenza viruses. Intranasal vaccination can improve local mucosal immune responses by preventing influenza infection at the portal of virus entry.
In the influenza virus, HA is a protein that plays a crucial role in the early stages of virus infection. Influenza HA has a head region and stalk region. Current influenza vaccines elicit immune responses against the HA head, but this head region is highly changeable and accounts for lowered efficiency against different strains. The HA stalk region is more conservative across different strains of influenza viruses.
Protein antigens that are administered intranasally are usually less able to provoke an immune response, so adjuvants are needed to have highly efficient intranasal vaccines. Adjuvants, such as CpG, can enhance and manipulate immune responses, thus improving the potency and breadth of protection.
“The PEI-HA/CpG nanoparticles show good potential as a cross-protective influenza vaccine candidate,” said Dr. Baozhong Wang, corresponding author of the study and a professor in the Institute for Biomedical Sciences at Georgia State. “The combination of PEI and CpG in the PEI-HA/CpG nanoparticle group contributed to the multifaceted immune responses, leading to vigorous cross protection. The incorporation of CpG and antigens into the same nanoparticle enhanced cellular immune responses.
“Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, or the ability to provoke an immune response, providing cross protection against different influenza virus strains. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups.”
“Nanoparticle platforms have shown intriguing characteristics and great potentials in the development of next-generation cross-protective influenza vaccines,” said Dr. Chunhong Dong, the first author of the study and a postdoctoral fellow in the Institute for Biomedical Sciences. “However, challenges exist to the successful research and development of nanoparticle vaccines. Though no apparent adverse effects were observed in the study, a more comprehensive safety evaluation of the nanoparticle adjuvant system is needed before clinical trials.”
Original Article: Intranasal Flu Vaccine with Nanoparticles Offers Robust Protection, Researchers Find
More from: Georgia State University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Influenza vaccine
- Influenza Vaccination: Addressing Safety Concerns and Maximizing Coverage - Dr Pradeep Suryawanshi
Influenza, also known as the flu, remains a significant public health challenge not only in India, but globally also, contributing to severe illnesses particularly among high-risk ...
- AstraZeneca's Covid vaccine may cause blood clotting: Should you be worried?
India Today spoke about AstraZeneca's admission about the rare side effect TTS triggered by its Covid-19 vaccine.
- Anti-vaccine website falsely claims Covid jabs behind cancer uptick
Studies show that Covid-19 shots save lives, but anti-vaccine advocates claim they have caused a huge spike in US cancer cases since the pandemic. This is false; the social media users and websites ...
- Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its ...
- New study offers promising targets for universal influenza B vaccine
In a milestone study led by the Peter Doherty Institute of Infection and Immunity (Doherty Institute), researchers have identified fragments from influenza B viruses that the immune system ...
Go deeper with Google Headlines on:
Influenza vaccine
[google_news title=”” keyword=”influenza vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanoparticle influenza vaccine
- Vaccines News
2024 — A vaccine against Zika virus is safe and effective when administered both before and during pregnancy, according to new ... New Antibodies Target 'Dark Side' of Influenza Virus Protein ...
- Is There a Vaccine for H5N1 Influenza?
On the heels of a multi-state outbreak of highly pathogenic avian influenza A (H5N1) in dairy cows, experts told MedPage Today that a trio of H5N1 vaccines for humans has already been developed and ...
- Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target ...
- Experts in Industry Wrangle Over Whether Combo Vaccines Are Beneficial for Adults
Despite rates of hospitalizations and deaths from COVID-19 being two to five times higher than those for influenza, people don't question flu vaccines the way they do COVID vaccines, Ceddia said ...
- Researchers develop more broadly protective coronavirus vaccine
The team presented their findings in research titled "Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine," published in ...
Go deeper with Google Headlines on:
Nanoparticle influenza vaccine
[google_news title=”” keyword=”nanoparticle influenza vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]